human | Q5 |
P106 | occupation | researcher | Q1650915 |
Q34273968 | Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. |
Q45419330 | Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma |
Q46561276 | Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients |
Q34876434 | CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients |
Q48034648 | Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis |
Q104059773 | Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant |
Q37042225 | Clinical responses with T lymphocytes targeting malignancy-associated κ light chains |
Q45864372 | Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia |
Q36941738 | Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia |
Q36059593 | Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer |
Q36399791 | Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease |
Q59351745 | EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation |
Q52598637 | High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease. |
Q35848688 | Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. |
Q57493527 | In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas |
Q37263151 | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study |
Q45862722 | Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals |
Q40092234 | Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation |
Q42678254 | Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression |
Q45880996 | Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine |
Q35068768 | Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins |
Q98164177 | The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma |
Q47218634 | Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma |
Q37707135 | Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. |
Search more.